Phase I Study of ABTL0812 in Combination with FOLFIRINOX for First-line Treatment in Patients with Metastatic Pancreatic Cancer
Summary
The purpose of this phase I/II trial is to evaluate the safety and efficacy of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
General Information
NCT#: NCT04431258
Study ID: ABT-C11-2020
Trial Phase: Phase I/II
Trial Sponsor: Ability Pharmaceuticals SL
Therapies Used in This Trial: FOLFIRINOX, ABTL0812